ALL

Question 1

Preferred treatment of Ph+ ALL

Answer 1

Multi-agent chemo (ex. hyper-CVAD) + TKI

Question 2

3 major toxicities of vinca alkaloids

Answer 2

Constipation
Peripheral neuropathy
Liver toxicity

Question 3

Use of pegasparagase in treatment of ALL

Answer 3

In combo with chemo in Ph- ALL

Question 4

5 class SEs of TKIs

Answer 4

Myelosuppression
Rash
GI upset
Fluid retention 
Liver toxicity

Question 5

Specific SE of imatinib

Answer 5

Orbital edema

Question 6

Specific SE of nilotinib

Answer 6

QT prolongation

Question 7

Specific SE of dasatinib

Answer 7

pleural effusion

Question 8

Specific SE of bosutinib

Answer 8

Diarrhea

Question 9

Most toxic TKI

Answer 9

Ponatinib

Question 10

Place in therapy for nelarabine in treating ALL

Answer 10

Refractory T-cell ALL

Question 11

MOA of nelarabine

Answer 11

prodrug that is demethylated to ara-G which is then incorporated into the DNA of leukemic blasts

Question 12

MOA of blinatumomab

Answer 12

Bispecific CD19 directed CD3 T-cell engager

Question 13

Indication of binatumomab in ALL

Answer 13

Ph- refractory B-cell precursor ALL

Question 14

Black box warning for blinatumomab

Answer 14

Cytokine release syndrome and neurological toxicities

Question 15

Typical maintenance therapy for ALL

Answer 15

daily 6-MP + weekly MTX +/- vincristine and corticosteroids